Literature DB >> 16498082

Proteinase-activated receptor2 agonists upregulate granulocyte colony-stimulating factor, IL-8, and VCAM-1 expression in human bronchial fibroblasts.

Rithwik Ramachandran1, Alyn H Morice, Steven J Compton.   

Abstract

Proteinase-activated receptors (PARs) are a novel family of G-protein-coupled receptors. PAR2 has been implicated in inflammatory airways disease. Although fibroblasts are pathologically important in the airways, the proinflammatory role of PAR2 in these cells remains unknown. We assessed PAR expression and functionality in human primary bronchial fibroblasts (HPBFs) before assessing PAR2-mediated HPBF proliferation, cytokine production, and adhesion molecule expression. RT-PCR and flow cytometry demonstrated that HPBFs express hPAR1, hPAR2, and hPAR3, but not hPAR4. Intracellular calcium signaling in HPBFs in response to PAR agonists showed that only hPAR1 and hPAR2 were functional receptors. We used the MTT assay to assess HPBF proliferation. Of the PAR2 agonist proteinases or selective PAR2-activating peptides (PAR2-APs) tested, none stimulated HPBF proliferation, whereas thrombin was a HPBF growth factor. mRNA for IL-8 and granulocyte colony-stimulating factor (G-CSF) was upregulated after addition of SLIGKV-NH2 when assessed by RT-PCR. No significant increase in G-CSF or IL-8 protein was detected. Trypsin stimulated IL-8 and G-CSF release from HPBF in a time- and dose-dependent manner. Leupeptin and soya trypsin inhibitor abrogated trypsin-stimulated cytokine release, indicating a requirement for trypsin's proteolytic activity. Trypsin and SLIGKV-NH2 stimulated an increase in VCAM-1 expression at 12 h after treatment, which declined thereafter. PAR2-driven upregulation of VCAM-1 cell surface expression and the release of IL-8 and G-CSF from bronchial fibroblasts may be important in promoting neutrophilic airways inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498082     DOI: 10.1165/rcmb.2005-0362OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  10 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

3.  PAR2 Modulators Derived from GB88.

Authors:  Mei-Kwan Yau; Ligong Liu; Jacky Y Suen; Junxian Lim; Rink-Jan Lohman; Yuhong Jiang; Adam J Cotterell; Grant D Barry; Jeffrey Y W Mak; David A Vesey; Robert C Reid; David P Fairlie
Journal:  ACS Med Chem Lett       Date:  2016-10-10       Impact factor: 4.345

Review 4.  Protease-activated receptors and prostaglandins in inflammatory lung disease.

Authors:  Terence Peters; Peter J Henry
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

5.  Tissue factor, blood coagulation, and beyond: an overview.

Authors:  Arthur J Chu
Journal:  Int J Inflam       Date:  2011-09-20

6.  Activation of protease-activated receptors (PARs)-1 and -2 promotes alpha-smooth muscle actin expression and release of cytokines from human lung fibroblasts.

Authors:  Nithiananthan Asokananthan; Rommel S Lan; Peter T Graham; Anthony J Bakker; Ana Tokanović; Geoffrey A Stewart
Journal:  Physiol Rep       Date:  2015-02-06

7.  Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis.

Authors:  Alistair G Tindell; Elizabeth B Kelso; William R Ferrell; John C Lockhart; David A Walsh; Lynette Dunning; Iain B McInnes
Journal:  Rheumatol Int       Date:  2011-09-13       Impact factor: 2.631

Review 8.  Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation.

Authors:  Huiyun Zhang; Xiaoning Zeng; Shaoheng He
Journal:  Mediators Inflamm       Date:  2014-04-30       Impact factor: 4.711

Review 9.  The role of granulocyte colony‑stimulating factor in breast cancer development: A review.

Authors:  Li Liu; Yangyang Liu; Xiaohua Yan; Chong Zhou; Xiangyang Xiong
Journal:  Mol Med Rep       Date:  2020-03-10       Impact factor: 2.952

10.  Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2.

Authors:  Yohan Seo; Chin Hee Mun; So-Hyeon Park; Dongkyu Jeon; Su Jeong Kim; Taejun Yoon; Eunhee Ko; Sungwoo Jo; Yong-Beom Park; Wan Namkung; Sang-Won Lee
Journal:  Int J Mol Sci       Date:  2020-07-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.